122 related articles for article (PubMed ID: 27459537)
1. GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.
Danielpur L; Sohn YS; Karmi O; Fogel C; Zinger A; Abu-Libdeh A; Israeli T; Riahi Y; Pappo O; Birk R; Zangen DH; Mittler R; Cabantchik ZI; Cerasi E; Nechushtai R; Leibowitz G
J Clin Endocrinol Metab; 2016 Oct; 101(10):3592-3599. PubMed ID: 27459537
[TBL] [Abstract][Full Text] [Related]
2. Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.
Kondo M; Tanabe K; Amo-Shiinoki K; Hatanaka M; Morii T; Takahashi H; Seino S; Yamada Y; Tanizawa Y
Diabetologia; 2018 Oct; 61(10):2189-2201. PubMed ID: 30054673
[TBL] [Abstract][Full Text] [Related]
3. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
4. Disruption of CR6-interacting factor-1 (CRIF1) in mouse islet beta cells leads to mitochondrial diabetes with progressive beta cell failure.
Kim YK; Joung KH; Ryu MJ; Kim SJ; Kim H; Chung HK; Lee MH; Lee SE; Choi MJ; Chang JY; Hong HJ; Kim KS; Lee SH; Kweon GR; Kim H; Lee CH; Kim HJ; Shong M
Diabetologia; 2015 Apr; 58(4):771-80. PubMed ID: 25660120
[TBL] [Abstract][Full Text] [Related]
5. A Combined Drug Treatment That Reduces Mitochondrial Iron and Reactive Oxygen Levels Recovers Insulin Secretion in NAF-1-Deficient Pancreatic Cells.
Karmi O; Sohn YS; Marjault HB; Israeli T; Leibowitz G; Ioannidis K; Nahmias Y; Mittler R; Cabantchik IZ; Nechushtai R
Antioxidants (Basel); 2021 Jul; 10(8):. PubMed ID: 34439408
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Lactococcus lactis expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro.
Zeng Z; Yu R; Zuo F; Zhang B; Ma H; Chen S
Appl Microbiol Biotechnol; 2017 Oct; 101(19):7177-7186. PubMed ID: 28828521
[TBL] [Abstract][Full Text] [Related]
7. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
Molina Vega M; Muñoz-Garach A; Tinahones FJ
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
[TBL] [Abstract][Full Text] [Related]
9. Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.
Kim MK; Cho JH; Lee JJ; Cheong YH; Son MH; Lee KJ
PLoS One; 2013; 8(9):e73340. PubMed ID: 24069189
[TBL] [Abstract][Full Text] [Related]
10. Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.
Sedman T; Rünkorg K; Krass M; Luuk H; Plaas M; Vasar E; Volke V
J Diabetes Res; 2016; 2016():9239530. PubMed ID: 27069934
[TBL] [Abstract][Full Text] [Related]
11. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.
Fan R; Li X; Gu X; Chan JC; Xu G
Diabetes Obes Metab; 2010 Sep; 12(9):815-24. PubMed ID: 20649634
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress.
Yusta B; Baggio LL; Estall JL; Koehler JA; Holland DP; Li H; Pipeleers D; Ling Z; Drucker DJ
Cell Metab; 2006 Nov; 4(5):391-406. PubMed ID: 17084712
[TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4.
Lietzau G; Nyström T; Östenson CG; Darsalia V; Patrone C
Oncotarget; 2016 Feb; 7(5):5865-76. PubMed ID: 26744321
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway.
Chang G; Liu J; Qin S; Jiang Y; Zhang P; Yu H; Lu K; Zhang N; Cao L; Wang Y; Li Y; Zhang D
Int J Mol Med; 2018 Mar; 41(3):1693-1703. PubMed ID: 29286061
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes.
Góralska J; Śliwa A; Gruca A; Raźny U; Chojnacka M; Polus A; Solnica B; Malczewska-Malec M
Acta Biochim Pol; 2017; 64(3):423-429. PubMed ID: 28822994
[TBL] [Abstract][Full Text] [Related]
17. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.
Wei R; Ma S; Wang C; Ke J; Yang J; Li W; Liu Y; Hou W; Feng X; Wang G; Hong T
Am J Physiol Endocrinol Metab; 2016 Jun; 310(11):E947-57. PubMed ID: 27072494
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Exposure of Pancreatic β-Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response.
Natalicchio A; Biondi G; Marrano N; Labarbuta R; Tortosa F; Spagnuolo R; D'Oria R; Carchia E; Leonardini A; Cignarelli A; Perrini S; Laviola L; Giorgino F
Endocrinology; 2016 Jun; 157(6):2243-58. PubMed ID: 27035653
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
20. Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.
van Raalte DH; Bunck MC; Smits MM; Hoekstra T; Cornér A; Diamant M; Eliasson B; Marja-RiittaTaskinen ; Heine RJ; Smith U; HanneleYki-Järvinen ; Mari A
Eur J Endocrinol; 2016 Oct; 175(4):345-52. PubMed ID: 27466218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
